News

Tuesday, July 28, 2-3:15 p.m. ET. The postpartum period can be especially challenging for mothers with opioid use disorder (OUD). Caring for an infant, sleep deprivation, perinatal mood and anxiety disorders, and disruptions in insurance coverage or treatment access can increase stress and elevate the risk of substance use recurrence.

SAMHSA recently signed a Dear Colleague letter with ACF and CMS on Expanding Access to Medications for Opioid Use Disorder (MOUD) Through Pharmacist State Scope-of-Practice Flexibility.

GLP-1 Receptor Agonists and Alcohol Use Disorder: Emerging Science and Clinical Innovation with Dr. Adam Scioli

As part of the Great American Recovery Initiative, the Department of Health & Human Services (HHS) is requesting input on research, programs, policies and strategies to improve substance use and mental illness prevention, treatment and recovery efforts. Comments Due: Sunday, July 5, 2026.

This study of Medicaid records from 29,193 women found that pregnant women who received OUD treatment, including medication, talk-based therapies, or both, had significantly better pregnancy outcomes than those who received no treatment.

SAMHSA has issued a new case study guide. This publication summarizes information about the postpartum period, presents an innovative program as a case study, and offers practical advice for care teams on comprehensive, collaborative perinatal care.